Clinical Trial Update: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating alpelisib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer after prior CDK4/6 inhibitor and aromatase inhibitor th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Piqray (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING